21 C.F.R. §1306.07 - Administering or dispensing of narcotic drugs

Cite as21 C.F.R. §1306.07
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
9 cases
  • U.S. v. Hayes, 84-1276
    • United States
    • United States Courts of Appeals. United States Court of Appeals (9th Circuit)
    • May 9, 1986
    ...the existence of a medical complaint and the appropriateness of treatment." The instruction, however, properly states the law. See 21 C.F.R. Sec. 1306.07(c) (1985). If a patient were a narcotic addict and the only medical complaint was addiction or withdrawal, Hayes could not have issued th......
  • Kerns v. Hoppe, 55615.
    • United States
    • Nevada Supreme Court of Nevada
    • March 21, 2012
    ...central nervous system depressant—OxyContin—in violation of state and federal law and without adequate monitoring and supervision. See 21 C.F.R. § 1306.07 (stating that in order for a practitioner to prescribe methadone to an addict without obtaining a DEA registration, the practitioner mus......
  • United States v. Ilayayev, s. 05–CR–836
    • United States
    • United States District Courts. 2nd Circuit. United States District Court (Eastern District of New York)
    • August 5, 2011
    ...drugs to persons with intractable pain in which no relief or cure is possible or none has been found after reasonable efforts.” 21 C.F.R. § 1306.07(c). Still, the federal government, through the CSA and the DEA's regulations, imposes significant limitations on who can issue and fill opioid ......
  • U.S. v. Cap Quality Care, Inc., Civil No. 05-163-P-H.
    • United States
    • United States District Courts. 1st Circuit. United States District Court (Maine)
    • May 2, 2007
    ...prescribing any Schedule II narcotic controlled drugs for maintenance or detoxification treatment."). 3. The government's brief cites 21 C.F.R. § 1306.07., a regulation that only indirectly supports the prohibition. Pl.'s Partial Objection to the Recommended Dec. (Docket Item 165) at 4 ('Pl......
  • Request a trial to view additional results
9 provisions
  • SB 319 – Revises laws relating to drugs
    • United States
    • Ohio Session Laws
    • January 1, 2016
    ...furnished to patients for the purpose of treating drug dependence or addiction, if the prescriber meets the conditions specified in 21 C.F.R. 1306.07;(2) Buprenorphine personally furnished to patients for the purpose of treating drug dependence or addiction as part of an opioid treatment pr......
  • HB 367 – To Require the Health Curriculum of Each School District to Include Instruction in Prescription Opioid Abuse Prevention...
    • United States
    • Ohio Session Laws
    • January 1, 2014
    ...to patients for the purpose of treating drug dependenceor addiction, if the prescriber meets the conditions specifiedin 21 C.F.R. 1306.07;(b) Buprenorphineprovided to patients for the purpose of treating drug dependenceor addiction, if the prescriber is exempt from separateregistration with......
  • Chapter 323, SB 193 – Pharmaceutical Amendments
    • United States
    • Utah Session Laws
    • January 1, 2023
    ...the qualified practitioner makes arrangements to refer the patient for substance use disorder treatment; and(b) in accordance with 21 C.F.R. Sec. 1306.07 and applicable regulation or guidance issued by the United States Drug Enforcement Administration regarding an emergency medical...
  • SB 260 – Regards abortion-inducing drugs
    • United States
    • Ohio Session Laws
    • January 1, 2020
    ...furnished to patients for the purpose of treating drug dependence or addiction, if the prescriber meets the conditions specified in 21 C.F.R. 1306.07;  (2) Buprenorphine personally furnished to patients for the purpose of treating drug dependence or addiction as part of an opioid treatment ......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT